Does the media prefer FBIO or AYTU?

In the previous week, Fortress Biotech had 5 more articles in the media than Aytu BioPharma. MarketBeat recorded 7 mentions for Fortress Biotech and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat Fortress Biotech's score of 0.86 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRCA or AYTU?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Aytu BioPharma's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.88 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PYPD or AYTU more profitable?

PolyPid has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% Aytu BioPharma -60.17% -69.93% -13.25%

Does the media prefer PYPD or AYTU?

In the previous week, PolyPid had 15 more articles in the media than Aytu BioPharma. MarketBeat recorded 17 mentions for PolyPid and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat PolyPid's score of 0.65 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AYTU or CGTX?

In the previous week, Cognition Therapeutics had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for Cognition Therapeutics and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat Cognition Therapeutics' score of 0.87 indicating that Aytu BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aytu BioPharma (AYTU) Competitors

$2.38 +0.08 (+3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 +0.00 (+0.21%)

As of 07:34 PM Eastern

Compare

AYTU vs. ALDX, FBIO, VRCA, PYPD, and CGTX

Should you buy Aytu BioPharma stock or one of its competitors? Aytu BioPharma's main competitors and comparable companies include Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), PolyPid (PYPD), and Cognition Therapeutics (CGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Aldeyra Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 252.56%. Aytu BioPharma has a consensus target price of $10.75, suggesting a potential upside of 351.68%. Given Aytu BioPharma's higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aytu BioPharma had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Aytu BioPharma and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.89 beat Aytu BioPharma's score of 0.93 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Very Positive
Aytu BioPharma	Positive

Aytu BioPharma has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aldeyra Therapeutics' return on equity of -53.14% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

Aldeyra Therapeutics and Aytu BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Fortress Biotech has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Fortress Biotech had 5 more articles in the media than Aytu BioPharma. MarketBeat recorded 7 mentions for Fortress Biotech and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat Fortress Biotech's score of 0.86 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.54	$6.82M	$3.17	0.92
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 480.20%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 351.68%. Given Fortress Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Fortress Biotech is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fortress Biotech has a net margin of 163.32% compared to Aytu BioPharma's net margin of -60.17%. Fortress Biotech's return on equity of 101.74% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	101.74%	46.34%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

Fortress Biotech beats Aytu BioPharma on 13 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Aytu BioPharma's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.88 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aytu BioPharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.40	-$17.89M	-$1.67	N/A
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

Aytu BioPharma has a net margin of -60.17% compared to Verrica Pharmaceuticals' net margin of -102.84%. Aytu BioPharma's return on equity of -69.93% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Verrica Pharmaceuticals currently has a consensus price target of $14.50, indicating a potential upside of 191.75%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 351.68%. Given Aytu BioPharma's higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aytu BioPharma beats Verrica Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to PolyPid?

PolyPid (NASDAQ:PYPD) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

PolyPid has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

PolyPid currently has a consensus price target of $11.33, indicating a potential upside of 139.10%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 351.68%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, PolyPid had 15 more articles in the media than Aytu BioPharma. MarketBeat recorded 17 mentions for PolyPid and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat PolyPid's score of 0.65 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aytu BioPharma has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PolyPid has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Summary

Aytu BioPharma beats PolyPid on 8 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Cognition Therapeutics?

Aytu BioPharma (NASDAQ:AYTU) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Cognition Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Cognition Therapeutics' return on equity of -50.17% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Aytu BioPharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aytu BioPharma has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

In the previous week, Cognition Therapeutics had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for Cognition Therapeutics and 2 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.93 beat Cognition Therapeutics' score of 0.87 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 351.68%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 230.03%. Given Aytu BioPharma's higher possible upside, equities research analysts clearly believe Aytu BioPharma is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cognition Therapeutics beats Aytu BioPharma on 9 of the 15 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.69M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.52	775.15	269.06	25.28
Price / Sales	0.38	743.86	602.43	91.76
Price / Cash	6.13	66.45	70.48	50.90
Price / Book	1.13	11.60	12.91	6.24
Net Income	-$13.56M	$2.77B	$3.45B	$347.60M
7 Day Performance	0.85%	0.17%	1.12%	1.07%
1 Month Performance	8.18%	0.35%	1.79%	1.03%
1 Year Performance	8.68%	161.52%	67.69%	20.77%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.7903 of 5 stars	$2.38 +3.5%	$10.75 +351.7%	+0.4%	$24.69M	$66.38M	N/A	160	News Coverage High Trading Volume
ALDX Aldeyra Therapeutics	3.442 of 5 stars	$1.55 +1.3%	$5.50 +254.8%	-73.2%	$92.29M	N/A	N/A	10	Positive News Gap Up
FBIO Fortress Biotech	2.6092 of 5 stars	$2.72 -1.4%	$17.00 +525.0%	+54.4%	$91.68M	$63.26M	0.86	170	News Coverage Earnings Report
VRCA Verrica Pharmaceuticals	3.0205 of 5 stars	$5.41 +3.0%	$14.50 +168.0%	-26.3%	$90.19M	$35.58M	N/A	40
PYPD PolyPid	3.1043 of 5 stars	$4.45 +2.1%	$11.33 +154.7%	+37.0%	$83.20M	N/A	N/A	80	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. ALDX, FBIO, VRCA, PYPD, and CGTX

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Summary

How does Aytu BioPharma compare to PolyPid?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. ALDX, FBIO, VRCA, PYPD, and CGTX

How does Aytu BioPharma compare to Aldeyra Therapeutics?

Which has more risk and volatility, ALDX or AYTU?

Do analysts recommend ALDX or AYTU?

Do institutionals & insiders hold more shares of ALDX or AYTU?

Does the media refer more to ALDX or AYTU?

Which has stronger valuation and earnings, ALDX or AYTU?

Is ALDX or AYTU more profitable?

Summary

How does Aytu BioPharma compare to Fortress Biotech?

Which has more risk & volatility, FBIO or AYTU?

Do insiders and institutionals have more ownership in FBIO or AYTU?

Does the media prefer FBIO or AYTU?

Which has better valuation and earnings, FBIO or AYTU?

Do analysts recommend FBIO or AYTU?

Is FBIO or AYTU more profitable?

Summary

How does Aytu BioPharma compare to Verrica Pharmaceuticals?

Which has more volatility & risk, VRCA or AYTU?

Does the media prefer VRCA or AYTU?

Do institutionals & insiders have more ownership in VRCA or AYTU?

Which has higher earnings & valuation, VRCA or AYTU?

Is VRCA or AYTU more profitable?

Do analysts recommend VRCA or AYTU?

Summary

How does Aytu BioPharma compare to PolyPid?

Which has more risk & volatility, PYPD or AYTU?

Do analysts recommend PYPD or AYTU?

Does the media prefer PYPD or AYTU?

Which has better earnings and valuation, PYPD or AYTU?

Do insiders and institutionals have more ownership in PYPD or AYTU?

Is PYPD or AYTU more profitable?

Summary

How does Aytu BioPharma compare to Cognition Therapeutics?

Is AYTU or CGTX more profitable?

Which has more volatility and risk, AYTU or CGTX?

Do institutionals and insiders have more ownership in AYTU or CGTX?

Which has preferable earnings & valuation, AYTU or CGTX?

Does the media favor AYTU or CGTX?

Do analysts prefer AYTU or CGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools